Healthcare Economics
Recently published articles about Cost and Economics
Original Research
Esketamine Nasal Spray vs Quetiapine ER in Treatment-Resistant Depression
January 27, 2025
Esketamine was associated with significantly larger improvements in work productivity loss and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives.
Recent JCP Articles on Cost and Economics
Original Research
Preference for Lisdexamfetamine vs CBT for Binge-Eating Disorder
May 7, 2025
CBT and pharmacotherapy with lisdexamfetamine resulted in significant improvements in binge-eating disorder. Participants’ preferences for treatments were not associated with sociodemographic or clinical characteristics and did not moderate treatment...
Commentary
Lower Risk of Cardiovascular Disorders in Antidepressant-Treated Women Veterans: Encouraging Findings but Concerns Remain
May 7, 2025
Comments on a study by Sumner et al that followed 609,546 women veterans for a mean of 8.8 years to look at associations of antidepressants with incident CVD.
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part II: Assessment
May 7, 2025
Consensus recommendations about the goals of a consultation for treatment-resistant depression include establishing the primary diagnosis and comorbidities, clarifying symptoms, identifying goals, documenting treatment history, identifying treatment barriers, and...
Recent PCC Articles on Cost and Economics
Case Report
Risperidone Long-Acting Injection Reduced Emergency Visits in a Patient With Comorbid Autism Spectrum and Borderline Personality Disorders
May 1, 2025
This case demonstrates that LAI risperidone may support emotional and interpersonal improvements in a patient with both borderline personality disorder and autism spectrum disorder.
